Back to Basics in the Diagnosis and Prognosis of Acute Myeloid Leukemia
Please complete Pre-test
Chapter 1 of 3
Release Date: May 31, 2017
Expiration Date: May 31, 2018
Expected time to complete this activity as designed: 45 minutes
There are no fees for participating in or receiving credit for this online activity.
The diagnosis and prognosis of acute myeloid leukemia (AML) is challenging due to complexities regarding disease biology, classification, and molecular markers. In May 2016, the World Health Organization (WHO) revised their classification of myeloid neoplasms and acute leukemia. Updates to practice guidelines and publication of data regarding investigational diagnostic and prognostic strategies are also changing how patients with suspected AML are diagnosed and assessed. In this activity, participants will learn the basics of diagnosing and prognosticating patients with AML using the recently revised clinical criteria, and will gain greater insight into today’s real-world issues associated with diagnosis, as well as diagnostic criteria and prognostic factors under investigation.
This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Identify patients suspected of acute myeloid leukemia (AML) and summarize diagnostic testing strategies that should be implemented
- Summarize revisions to the World Health Organization’s criteria for diagnosing and prognosticating AML and their impact on clinical practice
Back to Basics in the Diagnosis and Prognosis of Acute Myeloid Leukemia - Keith W. Pratz, MD
Instructions for Participation and Credit
This activity is eligible for credit through May 31, 2018. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Keith W. Pratz, MD
Assistant Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Dr. Keith Pratz received his medical degree from UMDNJ Robert Wood Johnson Medical School, Camden, New Jersey. He completed his residency in internal medicine at Mayo Graduate School of Medicine, Rochester, Minnesota, and his fellowship in medical oncology at The Johns Hopkins Hospital, Baltimore, Maryland. Dr. Pratz is a clinical investigator of novel therapeutics for acute leukemias and is an Assistant Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. He is the principal investigator on clinical trials incorporating novel targeted therapies into combination chemotherapy in acute leukemia. Dr. Pratz is also active in designing, coordinating, and conducting laboratory correlative studies in the setting of investigational therapies to aid in the development of improved treatments for hematologic malignancies.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Helsinn, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.
©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.75 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-151-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Keith Pratz has received grant support related to research activities from AbbVie Inc., Agios, Astellas Pharma US, Inc., and Millennium Pharmaceuticals, Inc.
Planning Committee Disclosures
The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.